Vanguard Group’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-2,125,480
| Closed | -$7.87M | – | 4121 |
|
|
2017
Q4 | $7.87M | Buy |
2,125,480
+245,440
| +13% | +$908K | ﹤0.01% | 2940 |
|
|
2017
Q3 | $7.69M | Buy |
1,880,040
+112,359
| +6% | +$460K | ﹤0.01% | 2943 |
|
|
2017
Q2 | $6.57M | Buy |
1,767,681
+343,838
| +24% | +$1.28M | ﹤0.01% | 2982 |
|
|
2017
Q1 | $5.9M | Buy |
1,423,843
+766,725
| +117% | +$3.17M | ﹤0.01% | 2996 |
|
|
2016
Q4 | $2.83M | Buy |
657,118
+76,948
| +13% | +$332K | ﹤0.01% | 3242 |
|
|
2016
Q3 | $5.71M | Buy |
580,170
+24,945
| +4% | +$245K | ﹤0.01% | 2941 |
|
|
2016
Q2 | $3.14M | Sell |
555,225
-40,331
| -7% | -$228K | ﹤0.01% | 3197 |
|
|
2016
Q1 | $4.54M | Buy |
595,556
+48,226
| +9% | +$367K | ﹤0.01% | 3004 |
|
|
2015
Q4 | $7.29M | Buy |
547,330
+3,867
| +0.7% | +$51.5K | ﹤0.01% | 2808 |
|
|
2015
Q3 | $8.93M | Buy |
543,463
+14,479
| +3% | +$238K | ﹤0.01% | 2669 |
|
|
2015
Q2 | $11.9M | Buy |
528,984
+28,757
| +6% | +$645K | ﹤0.01% | 2582 |
|
|
2015
Q1 | $4.89M | Buy |
500,227
+121,280
| +32% | +$1.19M | ﹤0.01% | 3010 |
|
|
2014
Q4 | $4.32M | Buy |
378,947
+29,999
| +9% | +$342K | ﹤0.01% | 2972 |
|
|
2014
Q3 | $4.02M | Buy |
348,948
+29,762
| +9% | +$343K | ﹤0.01% | 2951 |
|
|
2014
Q2 | $6.21M | Buy |
319,186
+25,085
| +9% | +$488K | ﹤0.01% | 2733 |
|
|
2014
Q1 | $5.28M | Buy |
294,101
+60,344
| +26% | +$1.08M | ﹤0.01% | 2797 |
|
|
2013
Q4 | $2.47M | Sell |
233,757
-26,338
| -10% | -$278K | ﹤0.01% | 3109 |
|
|
2013
Q3 | $3.22M | Buy |
260,095
+2,386
| +0.9% | +$29.5K | ﹤0.01% | 2944 |
|
|
2013
Q2 | $2.41M | Buy |
+257,709
| New | +$2.41M | ﹤0.01% | 3001 |
|